| pubmed-article:1918387 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1918387 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1918387 | lifeskim:mentions | umls-concept:C0021759 | lld:lifeskim |
| pubmed-article:1918387 | lifeskim:mentions | umls-concept:C0014457 | lld:lifeskim |
| pubmed-article:1918387 | lifeskim:mentions | umls-concept:C0029001 | lld:lifeskim |
| pubmed-article:1918387 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1918387 | pubmed:dateCreated | 1991-11-1 | lld:pubmed |
| pubmed-article:1918387 | pubmed:abstractText | To understand the role of the eosinophilopoietic cytokine IL-5 in humans, the posttreatment eosinophilic response in a group of microfilaria (mf)-positive patients with onchocerciasis (n = 10) was examined before and after treatment with diethylcarbamazine (6 mg/kg for 7 d). Sequential blood samples were assessed at 24 and 1 h before treatment (baseline values), then at frequent intervals over the next 14 d. Symptom scores, skin microfilariae (mf), and peripheral blood eosinophil counts were recorded as a function of time after treatment, and serum levels of IL-5 were quantitated by a highly sensitive (sensitivity greater than or equal to 20 pg/ml) monoclonal-based ELISA. Pretreatment eosinophil counts ranged from 240 to 1,186 eosinophils/microliter (geometric mean, 675), and the mf counts from 10 to 218 per mg skin (geometric mean, 79). After an initial decline in the peripheral eosinophil count to 28 +/- 8% of pretreatment levels at 8 h after beginning treatment, the eosinophil counts steadily increased over the next 2 wk, reaching a maximum at 14 d (257 +/- 38% of pretreatment levels). Serum levels of IL-5 rose sharply from pretreatment levels to a peak of 70.5 +/- 11 pg/ml by 24 h after treatment. Serum IL-5 remained elevated over the next 2-3 d and declined toward baseline by approximately 6 d after treatment, at which time the eosinophil levels were steadily increasing. IL-3 and granulocyte macrophage colony-stimulating factor, two other cytokines implicated in eosinophilopoeisis, were not detectable in the serum at any time before or after treatment. The rise in serum IL-5 before the posttreatment eosinophilia seen in this group of patients with onchocerciasis demonstrates a temporal relationship between IL-5 and the subsequent development of eosinophilia and implicates IL-5 as an important mediator of eosinophilia in humans. | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1918387 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:1918387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1918387 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1918387 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1918387 | pubmed:issn | 0021-9738 | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:OttesenE AEA | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:SilverJ EJE | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:AbramsJ SJS | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:NutmanT BTB | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:LimayeA PAP | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:AwadziKK | lld:pubmed |
| pubmed-article:1918387 | pubmed:author | pubmed-author:FrancisH FHF | lld:pubmed |
| pubmed-article:1918387 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1918387 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:1918387 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1918387 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1918387 | pubmed:pagination | 1418-21 | lld:pubmed |
| pubmed-article:1918387 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:meshHeading | pubmed-meshheading:1918387-... | lld:pubmed |
| pubmed-article:1918387 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:1918387 | pubmed:articleTitle | Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. | lld:pubmed |
| pubmed-article:1918387 | pubmed:affiliation | Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892. | lld:pubmed |
| pubmed-article:1918387 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1918387 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1918387 | lld:pubmed |
